Richie Cunningham, TYME Technologies CEO
January 26, 2022 10:20 AM EST
R&D

Mi­cro­cap can­cer play­er goes bel­ly up af­ter pan­cre­at­ic tu­mor hope­ful flops key study

Kyle Blankenship

TYME Tech­nolo­gies’ SM-88 has been pulled from a Phase II/III study af­ter a clin­i­cal tri­al spon­sor clued the biotech in on an ex­pect­ed fail­ure for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times